1112 On Other Exchanges
Symbol
Exchange
1112 is not on other exchanges.

biostime international holdi (1112) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSTIME INTERNATIONAL HOLDI (1112)

Related News

No related news articles were found.

biostime international holdi (1112) Related Businessweek News

No Related Businessweek News Found

biostime international holdi (1112) Details

Biostime International Holdings Limited, an investment holding company, provides pediatric nutritional and baby care products to mothers primarily in the People’s Republic of China. The company operates through five segments: Infant Formulas, Adult Nutrition and Care Products, Probiotic Supplements, Dried Baby Food and Nutrition Supplements, and Baby Care Products. The Infant Formulas segment produces infant formulas for children under seven years old and milk formulas for expectant and nursing mothers. The Adult Nutrition and Care Products segment offers vitamins, health supplements, skin care, and sports nutrition products for adults. The Probiotic Supplements segment produces probiotic supplements in the form of sachets, capsules, and tablets for infants, children, and expectant mothers. The Dried Baby Food and Nutrition Supplements segment engages in the production of dried baby food products made from natural foods for infants and young children; and microencapsulated milk calcium chewable tablets for children, and pregnant and lactating mothers. The Baby Care Products segment provides baby care products for infants and children, including baby diapers and toiletry kits, as well as personal care products for nursing mothers, such as nursing pads. The company is also involved in the wholesale, retail, import, and export of personal care products for infants; trading of infant food and nutritional products; early childhood education advisory business; and trading of related baby supplies, as well as offers online software and information technology services. It sells its products and services through distributors under the Biostime, Adimil, BMcare, and Parenting Power brands. The company was founded in 1999 and is headquartered in Guangzhou, China. Biostime International Holdings Limited is a subsidiary of Biostime Pharmaceuticals (China) Limited.

Founded in 1999

biostime international holdi (1112) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: CNY6.5M
Compensation as of Fiscal Year 2015.

biostime international holdi (1112) Key Developments

Biostime International Holdings Ltd. Enters into Purchase Agreement with Goldman Sachs

On 15 June 2016, Biostime International Holdings Ltd. entered into the purchase agreement with Goldman Sachs in connection with the issue of USD 400,000,000 7.25% Senior Notes due 2021. The gross proceeds of the Senior Notes Issue will be USD 400 million. The net proceeds after deduction of underwriting discount and certain expenses related to the Offer will be deposited into an escrow account pursuant to an escrow agreement. Approximately USD 250 million of the net proceeds of the Senior Notes Issue are expected to be released to repurchase Convertible Bonds tendered in the Offer and pay certain fees related to the Offer. The remaining net proceeds in the Escrow Account will be released from time to time in whole or in part, as applicable, in connection with any mandatory or optional redemption repayment or repurchase of the Convertible Bonds.

Biostime International Holdings Limited Reports Unaudited Consolidated Revenue Results for the Quarter Ended March 31, 2016

Biostime International Holdings Limited reported unaudited consolidated revenue results for the quarter ended March 31, 2016. For the quarter, the company reported total revenue of RMB 1,469 million compared to RMB 1,399.8 million a year ago.

Biostime International Holdings Limited Announces Management Changes, Effective 3 May, 2016

The board of directors of Biostime International Holdings Limited has announced that Mr. Wang Yidong has been appointed as the chief financial officer of the Group with effect from 3 May 2016. Mr. Wang has over 18 years of experience in financial management, accounting and corporate finance. Prior to joining the company, Mr. Wang was the Asia Pacific Vice President and Chief Finance Officer of Henkel AG & Co. KGaA responsible for Henkel's financial management, business and operation controlling as well as M&A-related tasks in 14 countries of Asia Pacific. Mr. Wang had also taken various financial management and banking roles with LG.Philips and JPMorgan Investment Bank in Hong Kong and New York. He started his career with China's Ministry of Commerce and participated in the negotiations for China's entry into the World Trade Organization. The board also announced that Mr. Cao Wenhui has resigned as the chief finance officer of the Group with effect from 3 May 2016 in order to pursue other business and professional endeavors.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1112 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1112.
View Industry Companies
 

Industry Analysis

1112

Industry Average

Valuation 1112 Industry Range
Price/Earnings 56.1x
Price/Sales 2.9x
Price/Book 4.3x
Price/Cash Flow 56.9x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BIOSTIME INTERNATIONAL HOLDI, please visit www.biostime.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.